ADXN News & Events

Addex Therapeutics Ltd - ADR trading halted, volatility trading pause

Addex Therapeutics announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is an orally available positive allosteric modulator of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. "The progression of NTX-253 into clinical studies represents an important milestone for both Neurosterix and Addex," said Tim Dyer, CEO of Addex Therapeutics. "Selective modulation of the M4 receptor through a PAM represents a novel therapeutic approach compared to traditional dopamine receptor antagonists and has the potential to provide patients suffering from schizophrenia with a differentiated efficacy and safety profile. We look forward to the progress of NTX-253 as it advances through clinical development."

Addex Therapeutics announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor positive allosteric modulator in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7 at the 10th American Cough Conference, in Dulles, Virginia by Mikhail Kalinichev, head of translational science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate.